Actively Recruiting
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
Led by Peking University Cancer Hospital & Institute · Updated on 2026-04-14
20
Participants Needed
1
Research Sites
98 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This project is driven by clinical needs and focuses on the mucin (MUC) family, key glycopeptide antigens involved in mediating immune evasion in solid tumors. We selected multiple members of this family as research subjects. Based on the MUC18 target, we developed the probe ⁸⁹Zr-SS-CNB001 (HuAA98-14, hereafter referred to as ⁸⁹Zr-s-C1). Studies have demonstrated that ⁸⁹Zr-s-C1 PET/CT enables noninvasive in vivo identification of tumor lesions in patients with solid tumors, and its imaging efficacy positively correlates with MUC18 expression levels in the patient's tumor tissue.
CONDITIONS
Official Title
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with pathologically confirmed newly diagnosed solid tumors or recent/suspected recurrence of previous solid tumors
- Both male and female patients eligible
- Hematology: WBC 64 4.0�d710�b9/L or neutrophil count 64 1.5�d710�b9/L, PLT 64 100�d710�b9/L, Hb 64 90 g/L, PT or APTT 4 1.5 �d7 upper limit of normal (ULN)
- Liver and kidney function: T-Bil 4 1.5 �d7 ULN, ALT and AST 4 2.5 �d7 ULN (or 4 5 �d7 ULN with liver metastases), ALP 4 2.5 �d7 ULN (or 4 4.5 �d7 ULN with bone/liver metastases), BUN 4 1.5 �d7 ULN, SCr 4 1.5 �d7 ULN
- Expected survival of at least 12 weeks
- Good compliance with follow-up
- At least one measurable target lesion per RECIST 1.1 criteria
- Female subjects must use effective contraception during the study and for 6 months after
- Male subjects must agree to use contraception during the study and for 6 months after
- Ability to understand and voluntarily sign the informed consent form
You will not qualify if you...
- Severe liver and kidney dysfunction
- Women preparing for pregnancy, pregnant, or breastfeeding
- Inability to lie flat for half an hour
- Inability to provide informed consent
- Claustrophobia or other psychiatric disorders
- Known allergy to the investigational drug or its excipients
- Other conditions deemed unsuitable for participation by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing cancer hosipitaal
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
Z
Zhangqian Zhang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here